Lucas Seibolt, MD
Interventional Cardiology · Valdosta, GANPI 1588074140
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.2%), grants and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.2% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $12,792, 7.9 times the $1,627 reported in 2019.
Across 478 payments — averaging $77.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$24K
- Abbott$7K
- E.r. Squibb & Sons, L.L.C.$708
- Abiomed$679
- Novartis$628
- Boehringer Ingelheim$627
- plus $4K from 25 others
What the payments were for
- Grants$12,00033%
- Travel & lodging$11,84032%
- Food & beverage$12,60934%
- Education$3801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 170 | $23,658 |
| Abbott | 14 | $6,519 |
| E.r. Squibb & Sons, L.L.C. | 47 | $708 |
| Abiomed | 13 | $679 |
| Novartis | 32 | $628 |
| Boehringer Ingelheim | 29 | $627 |
| Johnson & Johnson | 30 | $535 |
| AstraZeneca | 21 | $473 |
| Merck | 24 | $412 |
| Shockwave Medical, Inc | 10 | $347 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $303 |
| Medical Device Business Services, Inc. | 1 | $280 |
| Pfizer | 15 | $268 |
| Boston Scientific | 8 | $246 |
| Angiodynamics, Inc. | 1 | $166 |
| Amgen | 10 | $166 |
| Alnylam Pharmaceuticals Inc. | 6 | $153 |
| Edwards Lifesciences | 2 | $125 |
| Biosense Webster, Inc. | 7 | $119 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Bridgebio Pharma, Inc. | 3 | $57 |
| Atricure, Inc. | 2 | $55 |
| Kestra Medical Technology Services, Inc. | 3 | $53 |
| Lantheus Medical Imaging, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Inari Medical, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Cleerly, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Asahi Intecc USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,829 in reported general payments places this provider in the 80th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $126,070 |
| JardianceEmpagliflozin | 120 | $90,926 |
| EntrestoSacubitril/Valsartan | 58 | $48,926 |
| XareltoRivaroxaban | 68 | $44,046 |
| FarxigaDapagliflozin Propanediol | 40 | $28,914 |
| Repatha SureclickEvolocumab | 48 | $27,276 |
| Repatha PushtronexEvolocumab | 18 | $10,600 |
| BrilintaTicagrelor | 17 | $8,709 |
| Ranolazine ErRanolazine | 66 | $4,083 |
| Atorvastatin Calcium | 479 | $3,449 |
| ClopidogrelClopidogrel Bisulfate | 255 | $2,686 |
| Metoprolol Succinate | 326 | $2,681 |
| Valsartan | 105 | $1,601 |
| Amlodipine Besylate | 310 | $1,403 |
| Ezetimibe | 86 | $1,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $268 | $126,070170 claims |
| Boehringer IngelheimJardiance | $627 | $90,926120 claims |
| NovartisEntresto | $628 | $48,92658 claims |
| Johnson & JohnsonXarelto | $535 | $44,04668 claims |
| AstraZenecaFarxiga, Brilinta | $473 | $37,62357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Valdosta
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
- Katherine KunkelAtlanta$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.